One of the best con­nect­ed biotech star­tups in Boston snags a plum dis­cov­ery deal with No­var­tis

No­var­tis’ drug dis­cov­ery crew in­side the NI­BR cam­pus in Cam­bridge, MA is putting $30 mil­lion on the ta­ble to get a new TCR im­muno-on­col­o­gy pro­gram kicked off with one of the re­cent star­tups to de­but in the field — se­ri­ous mon­ey for what they be­lieve can of­fer an ef­fec­tive ap­proach to tack­ling sol­id tu­mors.

Christoph West­phal’s lat­est biotech cre­ation, TScan, lined up the deal, which drew in a No­var­tis crew at­tract­ed by their ap­proach in de­vel­op­ing TCR-en­gi­neered T cell ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.